Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib plus conventional chemotherapy for induction treatment in children with CBF-AML
ChiCTR-IIR-17013615Phase 3Recruiting
- Sponsor
- Shanghai Children's Medical Center
- Start
- Nov 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dasatinib in acute myeloid leukemia (AML) (2 arms), sponsored by Shanghai Children's Medical Center. Primary endpoints: Induction therapy complete remission rate and Depth of remission. Started Nov 2017; status: recruiting.
02
Drugs
dasatinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR-IIR-17013615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-17013615.